HUTCHMED DRC
Price & Volume
Stats
See more52W Range | $11.93-$21.92 |
Market Cap | $2.8B |
Shares Short | 601,165 |
Financials
See moreRevenue (12 Mos) | $610.8M |
Revenue Growth (YoY) | -42.6% |
Gross Profit (12 Mos) | -$271.5M |
Diluted EPS | -$0.25 |
News
See moreYahoo Finance • 3 months ago
HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status
Yahoo Finance • 9 months ago
HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms
Yahoo Finance • last year
HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China
Yahoo Finance • last year
HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer
About
CEO | Dr. Wei-Guo Su B.Sc., Ph.D. |
CFO | Mr. Chig Fung Cheng BEc, CA |
Address | Cheung Kong Center, Hong Kong, Hong Kong |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Full-Time Employees | 1,970 |
